These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24326003)

  • 21. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
    J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
    Del Prato S; Barnett AH; Huisman H; Neubacher D; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2011 Mar; 13(3):258-67. PubMed ID: 21205122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
    JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials.
    Inagaki N; Sheu WH; Owens DR; Crowe S; Bhandari A; Gong Y; Patel S
    J Diabetes Complications; 2016; 30(8):1622-1630. PubMed ID: 27499458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
    Mu Y; Pan C; Fan B; Hehnke U; Zhang X; Zhang X; Wang X; Liu J; Zhang Y; Du J; Ma J; Gong Y
    Diabetes Res Clin Pract; 2017 Feb; 124():48-56. PubMed ID: 28088030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Wu W; Li Y; Chen X; Lin D; Xiang S; Shen F; Gu X
    Med Sci Monit; 2015 Sep; 21():2678-84. PubMed ID: 26350766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
    Sheu WH; Park SW; Gong Y; Pinnetti S; Bhattacharya S; Patel S; Seck T; Woerle HJ
    Curr Med Res Opin; 2015 Mar; 31(3):503-12. PubMed ID: 25629790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Taskinen MR; Rosenstock J; Tamminen I; Kubiak R; Patel S; Dugi KA; Woerle HJ
    Diabetes Obes Metab; 2011 Jan; 13(1):65-74. PubMed ID: 21114605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Diabetes Obes Metab; 2015 Feb; 17(2):136-44. PubMed ID: 25298165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE).
    de Boer SA; Heerspink HJL; Juárez Orozco LE; van Roon AM; Kamphuisen PW; Smit AJ; Slart RHJA; Lefrandt JD; Mulder DJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1147-1154. PubMed ID: 28244635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
    Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
    Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
    Parthan G; Bhansali S; Kurpad AV; Walia R; Bhat K; Bhansali A
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):38. PubMed ID: 29970184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
    Tripolt NJ; Aberer F; Riedl R; Url J; Dimsity G; Meinitzer A; Stojakovic T; Aziz F; Hödl R; Brachtl G; Strunk D; Brodmann M; Hafner F; Sourij H
    Cardiovasc Diabetol; 2018 May; 17(1):71. PubMed ID: 29773079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
    Durán-Garcia S; Lee J; Yki-Järvinen H; Rosenstock J; Hehnke U; Thiemann S; Patel S; Woerle HJ
    Diabet Med; 2016 Jul; 33(7):926-33. PubMed ID: 26605991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study).
    Kim G; Lim S; Kwon HS; Park IB; Ahn KJ; Park CY; Kwon SK; Kim HS; Park SW; Kim SG; Moon MK; Kim ES; Chung CH; Park KS; Kim M; Chung DJ; Lee CB; Kim TH; Lee MK
    Diabetes Obes Metab; 2020 Sep; 22(9):1527-1536. PubMed ID: 32319168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.